[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-406543-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-406543-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","deciphering-the-role-of-cd47-in-cancer-immunotherapy","Deciphering the role of CD47 in cancer immunotherapy","","Immunotherapy has become a major strategy for cancer treatment, extending beyond surgery, radiotherapy, and chemotherapy. This review explains how immune checkpoint blockade and CAR-T therapies work, and focuses on CD47 as a critical “don’t eat me” checkpoint that suppresses innate immune signaling. It covers CD47’s high expression in many cancers, its interaction with SIRPa to prevent phagocytosis, and evidence from antibody and small-molecule targeting. It also discusses clinical challenges including anemia due to CD47 presence on erythrocytes, proposing possible strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/deciphering-the-role-of-cd47-in-cancer-immunotherapy/406543/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/deciphering-the-role-of-cd47-in-cancer-immunotherapy/406543.png","ImageObject",300,407,{"name":42,"@type":43},"A glass of water","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the role of CD47 in cancer immunotherapy?","Question",{"text":63,"@type":64},"CD47 functions as a checkpoint that transmits a “don’t eat me” signal, suppressing innate immune signaling and helping cancer cells evade immune surveillance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does CD47 prevent phagocytosis?",{"text":68,"@type":64},"CD47 is highly expressed in many cancers and protects cancer cells from phagocytosis by binding to SIRPa on phagocytes.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges arise when targeting CD47, and how might they be addressed?",{"text":72,"@type":64},"Targeting CD47 faces challenges such as anemia and related issues because CD47 is widely presented on erythrocytes; strategies may involve targeting CD47 regulators or the CD47 receptor interaction (SIRPa), including combination approaches.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},406543,1791127766,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},962090760832,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of Advanced Research 63 (2024) 129–158  \nContents lists available at ScienceDirect  \nJournal of Advanced Research  \njournal [homepage: www. elsevier. com/locate/jare](homepage: www. elsevier. com/locate/jare)  \nReview Article  \nDeciphering the role of CD47 in cancer immunotherapy  \nYu’e Liu a, 1, Linjun Weng a, 1, Yanjin Wang b, 1, Jin Zhang c, Qi Wu a, Pengcheng Zhao d, Yufeng Shi a,e, ⇑, Ping Wang a, ⇑, Lan Fang a, ⇑  \na Tongji University Cancer Center, Shanghai Tenth People’s Hospital of Tongji University, School of Medicine, Tongji University, Shanghai 200092, China b Department of Nephrology, Shanghai East Hospital, Tongji University, School of Medicine, Shanghai, China  \nc Department of Pharmacology and Toxicology, University of Mississippi, Medical Center, 39216 Jackson, MS, USA  \nd School of Life Sciences and Medicine, Shandong University of Technology, No.266 Xincun West Road, Zibo 255000, Shandong Province, China e Clinical Center for Brain and Spinal Cord Research, Tongji University, Shanghai 200092, China  \n| h i g h l i g h t s\u003Cbr>􀀁 CD47 has emerged as a target in cancer immunotherapy.\u003Cbr>􀀁 CD47 is highly expressed in cancers to prevent phagocytosis by phagocytes.\u003Cbr>􀀁 Targeting CD47 has been verified as a promising therapeutic strategy in cancer immunotherapy.\u003Cbr>􀀁 Antibodies and small molecules targeting CD47 exhibited both safety and efficacy in clinical trials.\u003Cbr>􀀁 Formidable challenges of targeting CD47 including anemia can be avoided by targeting the regulators of CD47 or its receptor SIRPa. |  | g r a p h i c a l a b s t r a c t\u003Cbr>|\n| --- | --- | --- |\n| a r t i c l e i n f o |  | a b s t r a c t |\n| Article history:\u003Cbr>Received 24 June 2023\u003Cbr>Revised 5 October 2023\u003Cbr>Accepted 18 October 2023\u003Cbr>Available online 28 October 2023 |  | Background: Immunotherapy has emerged as a novel strategy for cancer treatment following surgery, radiotherapy, and chemotherapy. Immune checkpoint blockade and Chimeric antigen receptor (CAR)-T cell therapies have been successful in clinical trials. Cancer cells evade immune surveillance by hijacking inhibitory pathways via overexpression of checkpoint genes. The Cluster of Differentiation 47 (CD47) has emerged as a crucial checkpoint for cancer immunotherapy by working as a ‘‘don’t eat me” signal and suppressing innate immune signaling. Furthermore, CD47 is highly expressed in many cancer types to protect cancer cells from phagocytosis via binding to SIRPa on phagocytes. Targeting CD47 by either interrupting the CD47-SIRPa axis or combing with other therapies has been demonstrated as an encouraging therapeutic strategy in cancer immunotherapy. Antibodies and small molecules that target CD47 have been explored in pre-and clinical trials. However, formidable challenges such as the anemia and palate aggregation cannot be avoided because of the wide presentation of CD47 on erythrocytes.\u003Cbr>Aim of view: This review summarizes the current knowledge on the regulation and function of CD47, and provides a new perspective for immunotherapy targeting CD47. It also highlights the clinical progress of targeting CD47 and discusses challenges and potential strategies.\u003Cbr>Key scientific concepts of review: This review provides a comprehensive understanding of targeting CD47 in cancer immunotherapy, it also augments the concept of combination immunotherapy strategies by employing both innate and adaptive immune responses.\u003Cbr>􀀁 2024 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)). |\n| Keywords:\u003Cbr>CD47 Phagocytosis Immunotherapy CD47-SIRPa |  |  |\n\n⇑ Corresponding authors at: Tongji University Cancer Center, Shanghai Tenth People’s Hospital of Tongji University, School of Medicine, Tongji University, Shanghai 200092, China.  \nE-mail [addresses:](addresses: yshi@tongji.edu.cn)[ yshi@tongji.edu.cn](add","cbCaibFvTZmx2byl","https://ap.wps.com/l/cbCaibFvTZmx2byl","pdf",3603766,"English","# Introduction\n# Basic knowledge of CD47\n## A brief history of CD47\n## The architecture of CD47\n## CD47 binding proteins\n## CD47 binds to Thrombospondin 1 (TSP-1)\n## CD47 binds to SIRPa\n## CD47 binds to SIRPc\n# CD47 regulation and function in cancer\n## Regulation of CD47\n## Transcriptional regulation of CD47","[{\"question\":\"What is the role of CD47 in cancer immunotherapy?\",\"answer\":\"CD47 functions as a checkpoint that transmits a “don’t eat me” signal, suppressing innate immune signaling and helping cancer cells evade immune surveillance.\"},{\"question\":\"How does CD47 prevent phagocytosis?\",\"answer\":\"CD47 is highly expressed in many cancers and protects cancer cells from phagocytosis by binding to SIRPa on phagocytes.\"},{\"question\":\"What challenges arise when targeting CD47, and how might they be addressed?\",\"answer\":\"Targeting CD47 faces challenges such as anemia and related issues because CD47 is widely presented on erythrocytes; strategies may involve targeting CD47 regulators or the CD47 receptor interaction (SIRPa), including combination approaches.\"}]","Deciphering the role of CD47 in cancer immunotherapy | PDF",1790566340,76]